305 related articles for article (PubMed ID: 22200179)
1. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
Wang G; Chan CH; Gao Y; Lin HK
Chin J Cancer; 2012 Apr; 31(4):169-77. PubMed ID: 22200179
[TBL] [Abstract][Full Text] [Related]
2. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
Bochis OV; Irimie A; Pichler M; Berindan-Neagoe I
J Gastrointestin Liver Dis; 2015 Jun; 24(2):225-34. PubMed ID: 26114183
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Skp2 expression and activity and its role in cancer progression.
Chan CH; Lee SW; Wang J; Lin HK
ScientificWorldJournal; 2010 Jun; 10():1001-15. PubMed ID: 20526532
[TBL] [Abstract][Full Text] [Related]
4. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
Lin HK; Chen Z; Wang G; Nardella C; Lee SW; Chan CH; Yang WL; Wang J; Egia A; Nakayama KI; Cordon-Cardo C; Teruya-Feldstein J; Pandolfi PP
Nature; 2010 Mar; 464(7287):374-9. PubMed ID: 20237562
[TBL] [Abstract][Full Text] [Related]
5. The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
Jamal A; Swarnalatha M; Sultana S; Joshi P; Panda SK; Kumar V
Cell Cycle; 2015; 14(16):2688-700. PubMed ID: 26038816
[TBL] [Abstract][Full Text] [Related]
6. Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex.
Wu J; Lee SW; Zhang X; Han F; Kwan SY; Yuan X; Yang WL; Jeong YS; Rezaeian AH; Gao Y; Zeng YX; Lin HK
Oncogene; 2013 Jan; 32(1):78-85. PubMed ID: 22310285
[TBL] [Abstract][Full Text] [Related]
7. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
Chen Q; Xie W; Kuhn DJ; Voorhees PM; Lopez-Girona A; Mendy D; Corral LG; Krenitsky VP; Xu W; Moutouh-de Parseval L; Webb DR; Mercurio F; Nakayama KI; Nakayama K; Orlowski RZ
Blood; 2008 May; 111(9):4690-9. PubMed ID: 18305219
[TBL] [Abstract][Full Text] [Related]
8. Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade.
Mickova A; Kharaishvili G; Kurfurstova D; Gachechiladze M; Kral M; Vacek O; Pokryvkova B; Mistrik M; Soucek K; Bouchal J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799604
[TBL] [Abstract][Full Text] [Related]
9. Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent.
Wei S; Chu PC; Chuang HC; Hung WC; Kulp SK; Chen CS
PLoS One; 2012; 7(10):e47298. PubMed ID: 23071779
[TBL] [Abstract][Full Text] [Related]
10. Specific small molecule inhibitors of Skp2-mediated p27 degradation.
Wu L; Grigoryan AV; Li Y; Hao B; Pagano M; Cardozo TJ
Chem Biol; 2012 Dec; 19(12):1515-24. PubMed ID: 23261596
[TBL] [Abstract][Full Text] [Related]
11. Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.
Huang KT; Pavlides SC; Lecanda J; Blank SV; Mittal KR; Gold LI
PLoS One; 2012; 7(9):e46072. PubMed ID: 23029392
[TBL] [Abstract][Full Text] [Related]
12. E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy.
Hao Z; Huang S
Front Biosci (Landmark Ed); 2015 Jan; 20(3):474-90. PubMed ID: 25553462
[TBL] [Abstract][Full Text] [Related]
13. Skp2 Inhibitors: Novel Anticancer Strategies.
Lee Y; Lim HS
Curr Med Chem; 2016; 23(22):2363-79. PubMed ID: 27160538
[TBL] [Abstract][Full Text] [Related]
14. The Skp2 Pathway: A Critical Target for Cancer Therapy.
Cai Z; Moten A; Peng D; Hsu CC; Pan BS; Manne R; Li HY; Lin HK
Semin Cancer Biol; 2020 Dec; 67(Pt 2):16-33. PubMed ID: 32014608
[TBL] [Abstract][Full Text] [Related]
15. Virtual drug design: Skp1-Skp2 inhibition targets cancer stem cells.
Pascal LE; Wang Z
Asian J Androl; 2013 Nov; 15(6):717-8. PubMed ID: 24077600
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
Chan CH; Morrow JK; Li CF; Gao Y; Jin G; Moten A; Stagg LJ; Ladbury JE; Cai Z; Xu D; Logothetis CJ; Hung MC; Zhang S; Lin HK
Cell; 2013 Aug; 154(3):556-68. PubMed ID: 23911321
[TBL] [Abstract][Full Text] [Related]
17. USP2 is an SKP2 deubiquitylase that stabilizes both SKP2 and its substrates.
Zhang F; Zhao Y; Sun Y
J Biol Chem; 2021 Oct; 297(4):101109. PubMed ID: 34425107
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL.
Rodriguez S; Abundis C; Boccalatte F; Mehrotra P; Chiang MY; Yui MA; Wang L; Zhang H; Zollman A; Bonfim-Silva R; Kloetgen A; Palmer J; Sandusky G; Wunderlich M; Kaplan MH; Mulloy JC; Marcucci G; Aifantis I; Cardoso AA; Carlesso N
Leukemia; 2020 May; 34(5):1241-1252. PubMed ID: 31772299
[TBL] [Abstract][Full Text] [Related]
19. Skp2 in the ubiquitin-proteasome system: A comprehensive review.
Asmamaw MD; Liu Y; Zheng YC; Shi XJ; Liu HM
Med Res Rev; 2020 Sep; 40(5):1920-1949. PubMed ID: 32391596
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2.
Ungermannova D; Gao Y; Liu X
J Biol Chem; 2005 Aug; 280(34):30301-9. PubMed ID: 15980415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]